Pavol Joppa1, Ruzena Tkacova2, Frits M E Franssen3, Corrine Hanson4, Stephen I Rennard5, Edwin K Silverman6, Merry-Lynn N McDonald7, Peter M A Calverley8, Ruth Tal-Singer9, Martijn A Spruit10, Klaus Kenn11, Emiel F M Wouters12, Erica P A Rutten3. 1. Department of Respiratory Medicine, PJ Safarik University, Kosice, Slovakia; Department of Research and Education, CIRO, Horn, Netherlands. Electronic address: joppapavol@gmail.com. 2. Department of Respiratory Medicine, PJ Safarik University, Kosice, Slovakia. 3. Department of Research and Education, CIRO, Horn, Netherlands. 4. Medical Nutrition Education, College of Allied Health Professions, University of Nebraska Medical Center, Omaha, NE. 5. Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, Omaha, NE; Clinical Discovery Unit, AstraZeneca, Cambridge, UK. 6. Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 7. Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 8. Pulmonary and Rehabilitation Medicine, University of Liverpool, Liverpool, UK. 9. GlaxoSmithKline, King of Prussia, PA. 10. Department of Research and Education, CIRO, Horn, Netherlands; REVAL-Rehabilitation Research Center, BIOMED-Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium. 11. Department of Respiratory Medicine and Pulmonary Rehabilitation, Schoen Klinik Berchtesgadener Land, Schoenau am Koenigssee, Germany. 12. Department of Research and Education, CIRO, Horn, Netherlands; Department of Respiratory Medicine, University of Maastricht, Maastricht, Netherlands.
Abstract
BACKGROUND: Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). OBJECTIVE: To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. DESIGN/SETTINGS/PARTICIPANTS: Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. MEASUREMENTS: All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. RESULTS: Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0-5.4, P < .001). In patients with COPD, SO was related to reduced 6-minute walking distance (-28.0 m, 95% CI -45.6 to -10.4), P < .01) and to higher systemic inflammatory burden (an elevation of at least 2 inflammatory markers, OR 1.6, 95% CI 1.1-2.5, P = .028) compared with the normal body composition group after adjustments for age, sex, smoking, body mass index, and airflow limitation. CONCLUSIONS: Our findings suggest that SO is associated with worse physical performance and higher systemic inflammatory burden compared with other body composition phenotypes in patients with COPD. TRIAL REGISTRY: ClinicalTrials.gov no. NCT00292552.
BACKGROUND: Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). OBJECTIVE: To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. DESIGN/SETTINGS/PARTICIPANTS: Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. MEASUREMENTS: All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. RESULTS:Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0-5.4, P < .001). In patients with COPD, SO was related to reduced 6-minute walking distance (-28.0 m, 95% CI -45.6 to -10.4), P < .01) and to higher systemic inflammatory burden (an elevation of at least 2 inflammatory markers, OR 1.6, 95% CI 1.1-2.5, P = .028) compared with the normal body composition group after adjustments for age, sex, smoking, body mass index, and airflow limitation. CONCLUSIONS: Our findings suggest that SO is associated with worse physical performance and higher systemic inflammatory burden compared with other body composition phenotypes in patients with COPD. TRIAL REGISTRY: ClinicalTrials.gov no. NCT00292552.
Authors: Michael Emmet O'Brien; Richard H Zou; Nathan Hyre; Joseph K Leader; Carl R Fuhrman; Frank C Sciurba; Mehdi Nouraie; Jessica Bon Journal: Thorax Date: 2021-12-01 Impact factor: 9.102
Authors: Lorena P Schneider; Larissa G Sartori; Felipe V C Machado; Daniele Dala Pola; Diery Fernandes Rugila; Raquel P Hirata; Mariana P Bertoche; Carlos A Camillo; Nidia A Hernandes; Karina C Furlanetto; Fabio Pitta Journal: Braz J Phys Ther Date: 2020-07-30 Impact factor: 3.377
Authors: Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield Journal: Ann Med Date: 2018-09-12 Impact factor: 4.709
Authors: Bruna S de Alencar Silva; Fábio S Lira; Fabrício E Rossi; Dionei Ramos; Juliana S Uzeloto; Ana P C F Freire; Fabiano F de Lima; Luís A Gobbo; Ercy M C Ramos Journal: Front Physiol Date: 2018-03-23 Impact factor: 4.566